hypothyroidism and glp-1 Benefits Risks of GLP-1s for Thyroid Health 10 Surprising Facts About GLP-1/GIP

In terms of achievement of HbA1c target, 81% and 97% of patients treated with tirzepatide reached an HbA1c less than 7%, while 71% and 95% of patients achieved a HbA1c of less than 6.5%

In a clinical trial involving individuals with established cardiovascular disease, retatrutide reduced the risk of major adverse cardiovascular events, including heart attacks, strokes, and cardiovascular death

If a Part D plan sponsor receives a prescription request for one of the three GLP-1 drugs it does not cover, CMS strongly encourages the sponsor to inform the prescribing physician to contact the central processor

But the mechanistic data is compelling enough that several research groups are exploring this avenue

However, 14 percent of survey respondents expressed an interest in taking GLP-1 agonists, the remaining 72.4 percent had not taken them

doi: 10.1016/j.metabol.2020.154272 25 CarusoICignarelliALaviolaLGiorginoF